NCT07918456
CPU-YL01 Injection in Patients With Chronic Hepatitis B.
StatusEnrolling by Invitation
PhasePhase 1
Primary completion (estimated)
At risk: Primary endpoint(s) modified.
See at-risk trials from Jiangsu Chuangyuan Life Science and Technology Co., Ltd.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary endpoint(s) modified
- Eligibility criteria shortened, about 6 words
- Secondary endpoints: 32 to 33
- Study title shortened, about 6 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
adverse events [Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration, observations will extend up to Day29 after the first dose; for multiple-dose administration, observations will extend up to Day337 after the first dose.
serious adverse events [Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration, observations will extend up to Day29 after the first dose; for multiple-dose administration, observations will extend up to Day337 after the first dose.
adverse events of particular concern (AESI) [Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration, observations will extend up to Day29 after the first dose; for multiple-dose administration, observations will extend up to Day337 after the first dose.
vital signs-Blood Pressure (mmHg) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: Screening, Day-1, Day1, Day2, Day3, Day8, Day15, Day22, Day29. Multiple-dose:Screening, Day-1, Day1,Day 2, Day3, Day8, Day36, Day29, Day57, Day85, Day113, Day141, Day142, Day143, Day148, Day169, Day225, Day281, and Day337.
vital signs-respiratory rate (breaths/min) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: Screening, Day-1, Day1, Day2, Day3, Day8, Day15, Day22, Day29. Multiple-dose: Screening, Day-1, Day1,Day 2, Day3, Day8, Day36, Day29, Day57, Day85, Day113, Day141, Day142, Day143, Day148, Day169, Day225, Day281, and Day337.
vital signs-body temperature (°C) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: Screening, Day-1, Day1, Day2, Day3, Day8, Day15, Day22, Day29. Multiple-dose: Screening, Day-1, Day1,Day 2, Day3, Day8, Day36, Day29, Day57, Day85, Day113, Day141, Day142, Day143, Day148, Day169, Day225, Day281, and Day337.
vital signs-pulse rate (beats/min) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: Screening, Day-1, Day1, Day2, Day3, Day8, Day15, Day22, Day29. Multiple-dose: Screening, Day-1, Day1,Day 2, Day3, Day8, Day36, Day29, Day57, Day85, Day113, Day141, Day142, Day143, Day148, Day169, Day225, Day281, and Day337.
physical examination- skin- Color abnormalities-jaundice -The number of participants with or without skin Color abnormalities- jaundice [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination- skin- Color abnormalities-pallor- The number of participants with or without skin Color abnormalities: pallor [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination- skin-Color abnormalities-pigmentation- The number of participants with or without skin Color abnormalities:pigmentation [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination- skin-Morphological abnormalities- rash-The number of participants with or without -Morphological abnormalities: rash [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination- skin-Morphological abnormalities-erythema at injection site -The number of participants with or without -Morphological abnormalities: erythema at injection site [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination- skin-Morphological abnormalities: induration at injection site- The number of participants with or without -Morphological abnormalities: induration at injection site [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-mucous membranes-Ocular conjunctiva: assessment for scleral icterus- The number of participants with or without -Ocular conjunctiva-scleral icterus [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-mucous membranes- Ocular conjunctiva: assessment for conjunctival pallor-The number of participants with or without -Ocular conjunctiva-conjunctival pallor [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-mucous membranes-Oral mucosa: assessment for petechiae-The number of participants with or without Oral mucosa-petechiae [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-mucous membranes-Oral mucosa: assessment for ulceration-The number of participants with or without Oral mucosa-ulceration [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-mucous membranes- Oral mucosa: assessment for fungal infection-The number of participants with or without Oral mucosa-fungal infection [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-lymph nodes- lymph nodes enlargement -The number of participants with or without lymph nodes enlargement [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-lymph nodes- Lymph Node Consistency(Participants with Enlarged Lymph Nodes)- The number of participants with lymph node consistency- soft, firm, hard. [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-lymph nodes-assessment for lymph nodes mobility (Participants with Enlarged Lymph Nodes) -The number of participants with lymph node mobility -mobile, fixed. [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-lymph nodes-assessment for tenderness (Participants with Enlarged Lymph Nodes) -The number of participants with lymph node tenderness tender, non-tender. [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-head-Face: assessment for dull facies-The number of participants with dull facies [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-head-Face: assessment for facial edema-The number of participants with facial edema [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-head-Eyes: assessment for eyelid edema-The number of participants with eyelid edema [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-head-Eyes: assessment for pupillary light reflex-The number of participants with normal, abnormal pupillary light reflex [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-head-assessment for alopecia- The number of participants with alopecia [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-neck-assessment for Thyroid Enlargement- The number of participants with Thyroid Enlargement [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-neck-assessment for Thyroid nodules-The number of participants with Thyroid nodules [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-neck-assessment of tracheal position-The number of participants with tracheal position midline / deviated [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-neck-assessment for nuchal rigidity-The number of participants with nuchal rigidity [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination- chest-Lungs: assessment of breath sound clarity-The number of participants with lung breath sounds clear, wheezes, rales. [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination- chest-Heart: assessment of cardiac rhythm regularity-The number of participants with cardiac rhythm regular, irregular. [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination- chest-Heart: assessment of cardiac murmur-The number of participants with cardiac murmur present, absent. [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-abdomen-Liver: assessment of Palpability of Liver Edge Below Right Midclavicular Costal Margin-The number of participants with the liver edge palpable, not palpable. [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-abdomen-Liver: Distance of Palpable Liver Edge Below the Right Midclavicular Costal Margin (centimeter)(For participants with a palpable liver edge)[Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-abdomen-Liver: assessment of hepatic consistency-The number of participants with hepatic consistency soft, firm, hard.(For participants with a palpable liver edge) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-abdomen-assessment for abdominal wall varices-The number of participants with abdominal wall varices [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-abdomen-assessment for abdominal tenderness-The number of participants with abdominal tenderness [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-abdomen-assessment for rebound tenderness-The number of participants with rebound tenderness. [Safety and Tolerability Evaluation Endpoints
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-abdomen-assessment for shifting dullness (indicative of ascites)-The number of participants-shifting dullness for ascites screening positive, negative. [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-abdomen-Spleen: assessment of Palpability of Spleen Edge Below Left Midclavicular Costal Margin-The number of participants with the splenic edge palpable, not palpable. [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination-abdomen-Spleen: Distance of Palpable Spleen Edge Below the Left Midclavicular Costal Margin (centimeter)(For participants with a palpable splenic edge ) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination- spine/limbs-Extremities: assessment for bilateral lower extremity edema-The number of participants with bilateral lower extremity edema [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination- spine/limbs-Extremities: assessment for joint erythema-The number of participants with joint erythema [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination- spine/limbs-Extremities: assessment for joint warmth -The number of participants with joint warmth [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination- spine/limbs-Extremities: assessment for joint tenderness -The number of participants with joint tenderness [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination- spine/limbs-Extremities: assessment for joint swelling -The number of participants with joint swelling [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination- spine/limbs-Spine: assessment for deformity The number of participants with Spine deformity. [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination- spine/limbs-Extremities: Spine: assessment for tenderness -The number of participants withwith Spine tenderness [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination- spine/limbs-Spine: assessment for limited range of motion The number of participants with limited range of motion . [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination--assessment of development- The number of participants with development good, fair, poor. [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination--assessment of nutritional status- The number of participants with nutritional status good, fair, poor. [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
physical examination--assessment of mental status- The number of participants with mental status alert, drowsy, agitated, comatose. [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening phase and then on Day-1, Day3, Day15, Day29. Multiple-dose: screening phase and then on Day-1, Day3, Day8, Day29,Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
12-lead electrocardiogram-heart rate [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day1, Day2, Day3, Day8, Day15, Day22, and Day29. Multiple-dose: screening, on Day-1, Day1,Day2, Day3, Day8, Day36, Day29, Day57, Day85, Day113, Day141, Day142, Day143, Day148, Day169, Day225, Day281, and Day337.
12-lead electrocardiogram-PR interval [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day1, Day2, Day3, Day8, Day15, Day22, and Day29. Multiple-dose: screening, on Day-1, Day1,Day2, Day3, Day8, Day36, Day29, Day57, Day85, Day113, Day141, Day142, Day143, Day148, Day169, Day225, Day281, and Day337.
12-lead electrocardiogram-RR interval [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day1, Day2, Day3, Day8, Day15, Day22, and Day29. Multiple-dose: screening, on Day-1, Day1,Day2, Day3, Day8, Day36, Day29, Day57, Day85, Day113, Day141, Day142, Day143, Day148, Day169, Day225, Day281, and Day337.
12-lead electrocardiogram-QRS [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day1, Day2, Day3, Day8, Day15, Day22, and Day29. Multiple-dose: screening, on Day-1, Day1,Day2, Day3, Day8, Day36, Day29, Day57, Day85, Day113, Day141, Day142, Day143, Day148, Day169, Day225, Day281, and Day337.
12-lead electrocardiogram-QT interval [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day1, Day2, Day3, Day8, Day15, Day22, and Day29. Multiple-dose: screening, on Day-1, Day1,Day2, Day3, Day8, Day36, Day29, Day57, Day85, Day113, Day141, Day142, Day143, Day148, Day169, Day225, Day281, and Day337.
12-lead electrocardiogram-QTcF [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day1, Day2, Day3, Day8, Day15, Day22, and Day29. Multiple-dose: screening, on Day-1, Day1,Day2, Day3, Day8, Day36, Day29, Day57, Day85, Day113, Day141, Day142, Day143, Day148, Day169, Day225, Day281, and Day337.
12-lead electrocardiogram-electrocardiographic diagnostic results [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day1, Day2, Day3, Day8, Day15, Day22, and Day29. Multiple-dose: screening, on Day-1, Day1,Day2, Day3, Day8, Day36, Day29, Day57, Day85, Day113, Day141, Day142, Day143, Day148, Day169, Day225, Day281, and Day337.
Clinical laboratory tests-hematology-red blood cell count (RBC) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day2, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day2, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-hematology-Concentration of hemoglobin (HGB) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day2, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day2, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-hematology-white blood cell count (WBC) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day2, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day2, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-hematology-absolute neutrophil count (ANC) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day2, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day2, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-hematology-platelet count (PLT) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day2, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day2, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Urinalysis-Concentration of urine protein (UPRO) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Urinalysis-count of urine red blood cells (RBC) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Urinalysis-count of urine white blood cells (WBC) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Urinalysis-Concentration of glucose (GLU-U) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Urinalysis-Concentration of ketones (KET) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Blood biochemistry-enzyme activity of alanine aminotransferase (ALT) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day2, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day2, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Blood biochemistry-enzyme activity of aspartate aminotransferase (AST) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day2, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day2, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Blood biochemistry-enzyme activity of γ-glutamyl transferase(γ-GGT) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day2, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day2, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Blood biochemistry-enzyme activity of alkaline phosphatase (ALP) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day2, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day2,Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Blood biochemistry-enzyme activity of cholinesterase (CHE) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day2, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day2, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Blood biochemistry-Concentration of albumin (ALB) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day2, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day2, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Blood biochemistry-Concentration of total protein (TP) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day2, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day2, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Blood biochemistry-Concentration of total bilirubin (TBil) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day2, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day2, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Blood biochemistry-Concentration of direct bilirubin (DBil) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day2, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day2, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Blood biochemistry-Concentration of serum creatinine (Cr) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Blood biochemistry-Concentration of serum uric acid (UA) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Blood biochemistry-Concentration of urea/blood urea nitrogen (Urea/BUN) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Blood biochemistry-Concentration of total cholesterol (TC) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Blood biochemistry-Concentration of triglycerides (TG) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Blood biochemistry-Concentration of high-density lipoprotein cholesterol (HDL-C) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Blood biochemistry-Concentration of low-density lipoprotein cholesterol (LDL-C) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Blood biochemistry-Concentration of serum glucose (GLU) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Blood biochemistry-Concentration of phosphorus ion levels [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Blood biochemistry-Concentration of potassium ion levels [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Blood biochemistry-Concentration of sodium ion levels [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Blood biochemistry-Concentration of chloride ion levels [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Blood biochemistry-Concentration of calcium ion levels [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Coagulation profile-prothrombin activity (PTA) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Coagulation profile-prothrombin time (PT) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Coagulation profile-Concentration of fibrinogen (FIB) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Coagulation profile-activated partial thromboplastin time (APTT) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Coagulation profile-thrombin time (TT) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Coagulation profile-International normalized ratio (INR) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests--Concentration of cTnI(cardiac Troponin I) or cTnT(cardiac Troponin T)[Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests--Concentration of C-reactive protein (CRP) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Immunological five-item panel- Concentration of immunoglobulin G (IgG) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Immunological five-item panel- Concentration of immunoglobulin A (IgA) [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Immunological five-item panel- Concentration of complement C4 [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
Clinical laboratory tests-Immunological five-item panel- Concentration of complement C3 [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: screening, Day-1, Day3, Day8, Day15, Day22, Day29. Multiple-dose: screening, Day-1, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day169, Day225, Day281, Day337.
abdominal ultrasound- liver-Liver size(millimeter) [Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration,abdominal ultrasound examinations were performed during the screening phase. For multiple-dose administration, abdominal ultrasound examinations were performed during the screening phase,and then on Day85, Day169, Day337.
abdominal ultrasound- liver-Hepatic Capsule - The number of participants with hepatic capsule findings normal, abnormal.[Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration,abdominal ultrasound examinations were performed during the screening phase. For multiple-dose administration, abdominal ultrasound examinations were performed during the screening phase,and then on Day85, Day169, Day337.
abdominal ultrasound- liver-Hepatic Parenchymal echotexture - The number of participants with hepatic parenchymal echotexture normal, abnormal.[Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration,abdominal ultrasound examinations were performed during the screening phase. For multiple-dose administration, abdominal ultrasound examinations were performed during the screening phase,and then on Day85, Day169, Day337.
abdominal ultrasound- liver-Portal Vein Internal Diameter (millimeter).[Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration,abdominal ultrasound examinations were performed during the screening phase. For multiple-dose administration, abdominal ultrasound examinations were performed during the screening phase,and then on Day85, Day169, Day337.
abdominal ultrasound- liver-intrahepatic biliary duct dilation-The number of participants with intrahepatic biliary duct dilation .[Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration,abdominal ultrasound examinations were performed during the screening phase. For multiple-dose administration, abdominal ultrasound examinations were performed during the screening phase,and then on Day85, Day169, Day337.
abdominal ultrasound- liver-extrahepatic biliary duct dilation-The number of participants with extrahepatic biliary duct dilation .[Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration,abdominal ultrasound examinations were performed during the screening phase. For multiple-dose administration, abdominal ultrasound examinations were performed during the screening phase,and then on Day85, Day169, Day337.
abdominal ultrasound- liver-Hepatic Solid Space-Occupying Lesion-The number of participants with the presence or absence of hepatic solid space-occupying lesions .[Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration,abdominal ultrasound examinations were performed during the screening phase. For multiple-dose administration, abdominal ultrasound examinations were performed during the screening phase,and then on Day85, Day169, Day337.
abdominal ultrasound- liver-Size of Hepatic Solid Space-Occupying Lesions (centimeter).( For participants with hepatic solid space-occupying lesions identified on abdominal ultrasound)[Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration,abdominal ultrasound examinations were performed during the screening phase. For multiple-dose administration, abdominal ultrasound examinations were performed during the screening phase,and then on Day85, Day169, Day337.
abdominal ultrasound-gallbladder-Gallbladder wall Thickness(millimeter) [Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration,abdominal ultrasound examinations were performed during the screening phase. For multiple-dose administration, abdominal ultrasound examinations were performed during the screening phase,and then on Day85, Day169, Day337.
abdominal ultrasound-gallbladder-gallstones-The number of participants with the presence or absence of gallstones[Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration,abdominal ultrasound examinations were performed during the screening phase. For multiple-dose administration, abdominal ultrasound examinations were performed during the screening phase,and then on Day85, Day169, Day337.
abdominal ultrasound-gallbladder-gallbladder polyps-The number of participants with the presence or absence of gallbladder polyps. [Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration,abdominal ultrasound examinations were performed during the screening phase. For multiple-dose administration, abdominal ultrasound examinations were performed during the screening phase,and then on Day85, Day169, Day337.
abdominal ultrasound-pancreas-Pancreatic Duct Internal Diameter(millimeter) [Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration,abdominal ultrasound examinations were performed during the screening phase. For multiple-dose administration, abdominal ultrasound examinations were performed during the screening phase,and then on Day85, Day169, Day337.
abdominal ultrasound-pancreas-Pancreatic Contour-The number of participants with pancreatic contour normal, abnormal. [Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration,abdominal ultrasound examinations were performed during the screening phase. For multiple-dose administration, abdominal ultrasound examinations were performed during the screening phase,and then on Day85, Day169, Day337.
abdominal ultrasound-spleen-Spleen Longitudinal Diameter (millimeter) [Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration,abdominal ultrasound examinations were performed during the screening phase. For multiple-dose administration, abdominal ultrasound examinations were performed during the screening phase,and then on Day85, Day169, Day337.
abdominal ultrasound-spleen-Spleen Thickness (millimeter) [Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration,abdominal ultrasound examinations were performed during the screening phase. For multiple-dose administration, abdominal ultrasound examinations were performed during the screening phase,and then on Day85, Day169, Day337.
abdominal ultrasound-spleen-Splenic Vein Internal Diameter(millimeter)[Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration,abdominal ultrasound examinations were performed during the screening phase. For multiple-dose administration, abdominal ultrasound examinations were performed during the screening phase,and then on Day85, Day169, Day337.
abdominal ultrasound-Ascites Volume-The number of participants with Ascites none, mild, moderate, or large volume[Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration,abdominal ultrasound examinations were performed during the screening phase. For multiple-dose administration, abdominal ultrasound examinations were performed during the screening phase,and then on Day85, Day169, Day337.
abdominal ultrasound-both kidneys-Renal cortical thickness(millimeter) [Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration,abdominal ultrasound examinations were performed during the screening phase. For multiple-dose administration, abdominal ultrasound examinations were performed during the screening phase,and then on Day85, Day169, Day337.
abdominal ultrasound-both kidneys--Renal Pelvic Dilation Diameter(millimeter) [Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration,abdominal ultrasound examinations were performed during the screening phase. For multiple-dose administration, abdominal ultrasound examinations were performed during the screening phase,and then on Day85, Day169, Day337.
abdominal ultrasound-both kidneys--renal cyst -The number of participants with the presence or absence of renal cysts. [Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration,abdominal ultrasound examinations were performed during the screening phase. For multiple-dose administration, abdominal ultrasound examinations were performed during the screening phase,and then on Day85, Day169, Day337.
abdominal ultrasound-both kidneys-Size of Renal Cyst (millimeter). (For participants with identified renal cysts). [Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration,abdominal ultrasound examinations were performed during the screening phase. For multiple-dose administration, abdominal ultrasound examinations were performed during the screening phase,and then on Day85, Day169, Day337.
abdominal ultrasound-both kidneys-Renal Stone -The number of participants with the presence or absence of -Renal Stone. [Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration,abdominal ultrasound examinations were performed during the screening phase. For multiple-dose administration, abdominal ultrasound examinations were performed during the screening phase,and then on Day85, Day169, Day337.
abdominal ultrasound-both kidneys-Size of Renal Stone (millimeter). (For participants with identified Renal Stone). [Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration,abdominal ultrasound examinations were performed during the screening phase. For multiple-dose administration, abdominal ultrasound examinations were performed during the screening phase,and then on Day85, Day169, Day337.
FibroScan-Liver stiffness value (LSM, unit: kPa)[Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration, FibroScan examinations were performed during the screening phase. For multiple-dose administration, FibroScan examinations were performed during the screening phase,and then on Day337.
FibroScan-Controlled Attenuation Parameter (CAP, unit: dB/m) [Safety and Tolerability Evaluation Endpoints]
Timeframe: For single-dose administration, FibroScan examinations were performed during the screening phase. For multiple-dose administration, FibroScan examinations were performed during the screening phase,and then on Day337.
injection site monitoring-Pain-Assessment of injection site monitoring-Pain graded using CTCAE Version 6.0. The number of participants in each category will be reported. [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: Day1, Day2, Day3, and Day8. Multiple-dose: Day1, Day2, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day142, Day143 and Day148.
injection site monitoring- Induration-Assessment of injection site monitoring-Induration graded using CTCAE Version 6.0. The number of participants in each category will be reported. [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: Day1, Day2, Day3, and Day8. Multiple-dose: Day1, Day2, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day142, Day143 and Day148.
injection site monitoring-swelling-Assessment of injection site monitoring-swelling graded using CTCAE Version 6.0. The number of participants in each category will be reported. [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: Day1, Day2, Day3, and Day8. Multiple-dose: Day1, Day2, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day142, Day143 and Day148.
injection site monitoring-Rash (erythema) -Assessment of injection site monitoring-Rash (erythema) graded using CTCAE Version 6.0. The number of participants in each category will be reported. [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: Day1, Day2, Day3, and Day8. Multiple-dose: Day1, Day2, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day142, Day143 and Day148.
injection site monitoring-Pruritus (at the injection site)-Assessment of injection site monitoring-Pruritus (at the injection site) graded using CTCAE Version 6.0. The number of participants in each category [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: Day1, Day2, Day3, and Day8. Multiple-dose: Day1, Day2, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day142, Day143 and Day148.
injection site monitoring-Phlegmon -Assessment of injection site monitoring-Phlegmon graded using CTCAE Version 6.0. The number of participants in each category will be reported. [Safety and Tolerability Evaluation Endpoints]
Timeframe: Single-dose: Day1, Day2, Day3, and Day8. Multiple-dose: Day1, Day2, Day3, Day8, Day29, Day36, Day57, Day85, Day113, Day141, Day142, Day143 and Day148.
Secondary (33)
Primary pharmacokinetic parameters (After a single/dose administration)-peak concentration (Cmax) [Pharmacokinetic Evaluation Parameters]
Primary pharmacokinetic parameters (After a single/dose administration)-time to reach peak concentration (Tmax) [Pharmacokinetic Evaluation Parameters]
Primary pharmacokinetic parameters (After a single/dose administration)-area under the plasma concentration-time curve from time 0 to the last measurable concentration time point (AUC0-t) [Pharmacokinetic Evaluation Parameters]
Primary pharmacokinetic parameters (After a single/dose administration)-area under the plasma concentration-time curve extrapolated from time 0 to infinity (AUC0-∞)[Pharmacokinetic Evaluation Parameters]
Primary pharmacokinetic parameters (After a single/dose administration) elimination rate constant (λz) [Pharmacokinetic Evaluation Parameters]
Show 28 moreShow less
Primary pharmacokinetic parameters (After a single/dose administration)-elimination half-life(t1/2)[Pharmacokinetic Evaluation Parameters]
Primary pharmacokinetic parameters (After a single/dose administration)-apparent clearance (CL/F) [Pharmacokinetic Evaluation Parameters]
Primary pharmacokinetic parameters (After a single/dose administration)-apparent volume of distribution(Vz/F)[Pharmacokinetic Evaluation Parameters]
Primary pharmacokinetic parameters (After a single/dose administration)-mean residence time(MRT0-t、MRT0-∞)[Pharmacokinetic Evaluation Parameters]
Primary pharmacokinetic parameters (After a single/dose administration)-percentage of residual area (AUC_%Extrap) [Pharmacokinetic Evaluation Parameters]
Primary pharmacokinetic parameters (After multiple dosing)- steady-state peak concentration(Cmax,ss) [Pharmacokinetic Evaluation Parameters]
Primary pharmacokinetic parameters (After multiple dosing)- steady-state trough concentration (Cmin,ss) [Pharmacokinetic Evaluation Parameters]
Primary pharmacokinetic parameters (After multiple dosing)- mean steady-state plasma concentration (Cav,ss) [Pharmacokinetic Evaluation Parameters]
Primary pharmacokinetic parameters (After multiple dosing)- steady-state time to peak concentration ( Tmax,ss) [Pharmacokinetic Evaluation Parameters]
Primary pharmacokinetic parameters (After multiple dosing)- area under the plasma concentration-time curve from time 0 after the last dose to the last measurable concentration time point (AUC0-t,ss) [Pharmacokinetic Evaluation Parameters]
Primary pharmacokinetic parameters (After multiple dosing)-area under the plasma concentration-time curve extrapolated from time 0 after the last dose to infinity ( AUC0-∞,ss) [Pharmacokinetic Evaluation Parameters]
Primary pharmacokinetic parameters (After multiple dosing)- elimination rate constant (λz) [Pharmacokinetic Evaluation Parameters]
Primary pharmacokinetic parameters (After multiple dosing)- elimination half-life (t1/2,ss) [Pharmacokinetic Evaluation Parameters]
Primary pharmacokinetic parameters (After multiple dosing)- steady-state apparent clearance (CLss/F) [Pharmacokinetic Evaluation Parameters]
Primary pharmacokinetic parameters (After multiple dosing)- steady-state apparent volume of distribution ( Vz,ss/F) [Pharmacokinetic Evaluation Parameters]
Primary pharmacokinetic parameters (After multiple dosing)- mean residence time (MRT0-∞) [Pharmacokinetic Evaluation Parameters]
Primary pharmacokinetic parameters (After multiple dosing)- fluctuation coefficient (DF) [Pharmacokinetic Evaluation Parameters]
Primary pharmacokinetic parameters (After multiple dosing)- accumulation index (Rac,AUC、Rac,Cmax) [Pharmacokinetic Evaluation Parameters]
Primary PD endpoints-quantitative HBsAg [Pharmacodynamic (efficacy) Evaluation Indicators]
Primary PD endpoints-quantitative HBsAb [Pharmacodynamic (efficacy) Evaluation Indicators]
Primary PD endpoints--quantitative anti-Pre-S1 [Pharmacodynamic (efficacy) Evaluation Indicators]
Primary PD endpoints--quantitative hepatitis B e antigen (HBeAg) [Pharmacodynamic (efficacy) Evaluation Indicators]
Primary PD endpoints--quantitative hepatitis B e antibody (HBeAb)[Pharmacodynamic (efficacy) Evaluation Indicators]
Primary PD endpoints--quantitative hepatitis B core antibody (HBcAb) [Pharmacodynamic (efficacy) Evaluation Indicators]
Primary PD endpoints--Pre-S1 Antigen Quantification [Pharmacodynamic (efficacy) Evaluation Indicators]
Secondary PD endpoints-HBV DNA quantification [Pharmacodynamic (efficacy) Evaluation Indicators]
Secondary PD endpoints-HBV RNA quantification [Pharmacodynamic (efficacy) Evaluation Indicators]
Secondary PD endpoints-hepatitis B core antigen (HBcrAg) quantification [Pharmacodynamic (efficacy) Evaluation Indicators]
Arms and interventions
CPU-YL01 InjectionExperimental
Intramuscular administration
Placbo InjectionPlacebo comparator
Intramuscular administration
Drugs: CPU-YL01 Injection Intramuscular administration, Placebo intramuscular injection
Sites
4 sites in 1 country